Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
227 hedge funds and large institutions have $4.06B invested in Blueprint Medicines in 2019 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 70 increasing their positions, 78 reducing their positions, and 26 closing their positions.
62% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 26
8% more capital invested
Capital invested by funds: $3.78B → $4.06B (+$286M)
4% more funds holding
Funds holding: 219 → 227 (+8)
1.59% less ownership
Funds ownership: 104.73% → 103.14% (-1.6%)
10% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 78
24% less call options, than puts
Call options by funds: $42M | Put options by funds: $55.2M
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$41.1M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$37.8M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$19.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.7M |
| 5 |
DM
Deerfield Management
New York
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$41.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.6M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$28.3M |
| 4 |
HM
HealthCor Management
New York
|
-$22.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$19.8M |
BPMC Hedge Fund Activity: Q4 2019 in Review
227 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2019, worth a combined $4.06B — up 7.6% from $3.78B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new BPMC positions and 26 closed out — a net gain of 16 holders — while 70 added to existing stakes and 78 trimmed.
The largest buyer was Cadian Capital Management, adding an estimated $41.1M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $41.1M sold.
- 227 institutional investors held Blueprint Medicines (BPMC) as of Q4 2019, up from 219 in Q3 2019.
- Funds reported $4.06B of Blueprint Medicines stock for Q4 2019, up 7.6% quarter-over-quarter.
- 42 funds opened new Blueprint Medicines positions in Q4 2019 and 26 closed out, a net change of +16 holders.
- The largest Blueprint Medicines buyer in Q4 2019 was Cadian Capital Management, an estimated $41.1M added.
- The largest Blueprint Medicines seller in Q4 2019 was Foresite Capital Management III, an estimated $41.1M sold.
Based on aggregated 13F filings for Q4 2019.